ZA962711B - Use of imidazol[1,2-a]pyridine-3-acetamide derivatives for the therapeutic treatment of neuropsychiatric syndromes associated with dysfunction of the neural circuits of the basal ganglia - Google Patents

Use of imidazol[1,2-a]pyridine-3-acetamide derivatives for the therapeutic treatment of neuropsychiatric syndromes associated with dysfunction of the neural circuits of the basal ganglia

Info

Publication number
ZA962711B
ZA962711B ZA962711A ZA962711A ZA962711B ZA 962711 B ZA962711 B ZA 962711B ZA 962711 A ZA962711 A ZA 962711A ZA 962711 A ZA962711 A ZA 962711A ZA 962711 B ZA962711 B ZA 962711B
Authority
ZA
South Africa
Prior art keywords
imidazol
dysfunction
pyridine
therapeutic treatment
basal ganglia
Prior art date
Application number
ZA962711A
Other languages
English (en)
Inventor
Elena Benincasa
Original Assignee
Elena Benincasa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elena Benincasa filed Critical Elena Benincasa
Publication of ZA962711B publication Critical patent/ZA962711B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA962711A 1995-04-07 1996-04-04 Use of imidazol[1,2-a]pyridine-3-acetamide derivatives for the therapeutic treatment of neuropsychiatric syndromes associated with dysfunction of the neural circuits of the basal ganglia ZA962711B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT95RM000223A IT1276522B1 (it) 1995-04-07 1995-04-07 Uso dello zolpidem per il trattamento terapeudico di sindromi neuropsichiatriche associate a disfunsione e di circuiti neurali dei

Publications (1)

Publication Number Publication Date
ZA962711B true ZA962711B (en) 1996-07-30

Family

ID=11403250

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA962711A ZA962711B (en) 1995-04-07 1996-04-04 Use of imidazol[1,2-a]pyridine-3-acetamide derivatives for the therapeutic treatment of neuropsychiatric syndromes associated with dysfunction of the neural circuits of the basal ganglia

Country Status (25)

Country Link
US (1) US5891891A (fr)
EP (1) EP0819002B1 (fr)
JP (1) JP4049390B2 (fr)
KR (1) KR100425628B1 (fr)
CN (1) CN1198612C (fr)
AR (1) AR003414A1 (fr)
AT (1) ATE222763T1 (fr)
AU (1) AU707759B2 (fr)
CA (1) CA2217590C (fr)
CZ (1) CZ292020B6 (fr)
DE (1) DE69623271T2 (fr)
DK (1) DK0819002T3 (fr)
EA (1) EA000396B1 (fr)
ES (1) ES2182967T3 (fr)
HU (1) HUP9900733A3 (fr)
IL (1) IL117824A (fr)
IT (1) IT1276522B1 (fr)
MX (1) MX9707712A (fr)
NO (1) NO315408B1 (fr)
NZ (1) NZ304107A (fr)
PL (1) PL322647A1 (fr)
PT (1) PT819002E (fr)
TW (1) TW450816B (fr)
WO (1) WO1996031210A1 (fr)
ZA (1) ZA962711B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7632517B2 (en) * 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US6333345B1 (en) 1999-05-14 2001-12-25 Sepracor, Inc. Methods of using and compositions comprising N-desmethylzolpidem
US6399621B1 (en) 1999-08-10 2002-06-04 American Cyanamid Company N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1, 5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
US6485746B1 (en) 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US20030091632A1 (en) * 1999-08-26 2003-05-15 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
US6384221B1 (en) 1999-09-02 2002-05-07 Neurocrine Biosciences, Inc. Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
WO2001078725A2 (fr) * 2000-04-13 2001-10-25 Synthon B.V. Formulations a liberation modifiee contenant un agent hypnotique
IL152411A0 (en) * 2000-04-24 2003-05-29 Teva Pharma Zolpidem hemitartrate
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE10117183A1 (de) * 2001-04-05 2002-10-10 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel
AU2004237943A1 (en) * 2003-05-19 2004-11-25 Sciencom Ltd Further therapeutic use of zolpidem
GB0311457D0 (en) * 2003-05-19 2003-06-25 Sciencom Ltd New therapeutic use
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
ATE454140T1 (de) 2004-02-18 2010-01-15 Sepracor Inc Dopamin-agonisten-kombinationstherapie mit sedativa zur verbesserung der schlafqualität
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
WO2007065559A1 (fr) * 2005-11-18 2007-06-14 Synthon B.V. Comprimés de zolpidem
GB2443928A (en) * 2006-11-08 2008-05-21 Regen Therapeutics Plc Transdermal pharmaceutical composition comprising Zolpidem
GB0809936D0 (en) * 2008-05-30 2008-07-09 Regen Therapeutics Plc Therapeutic use of zolpidem
EP3468545B1 (fr) 2016-06-08 2026-08-05 President and Fellows of Harvard College Procédés et compositions pour réduire le dysfonctionnement tactile et l'anxiété associés au trouble du spectre de l'autisme, au syndrome de rett et au syndrome de l'x fragile
WO2019226808A1 (fr) 2018-05-22 2019-11-28 President And Fellows Of Harvard College Compositions et procédés permettant de réduire un dysfonctionnement tactile, l'anxiété et une déficience sociale
EP3801512A4 (fr) 2018-05-29 2022-01-19 President and Fellows of Harvard College Compositions et méthodes pour réduire un dysfonctionnement tactile, l'anxiété et une déficience sociale
US12077512B2 (en) 2019-03-25 2024-09-03 President And Fellows Of Harvard College Compositions and methods for reducing tactile dysfunction, anxiety, and social impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492382A1 (fr) * 1980-10-22 1982-04-23 Synthelabo Derives d'imidazo (1,2-a) pyridine, leur preparation et leur application en therapeutique
US5032595A (en) * 1989-11-24 1991-07-16 Fidia-Georgetown Institute For The Neurosciences Method of stimulating steroidogenesis with alpidem
US5206382A (en) * 1991-06-27 1993-04-27 Fidia Georgetown Institute For The Neurosciences Indole derivatives, pharmaceutical compositions and methods of treating neurological and psychiatric disorders

Also Published As

Publication number Publication date
KR100425628B1 (ko) 2004-06-23
EA199700308A1 (ru) 1998-04-30
AR003414A1 (es) 1998-08-05
ATE222763T1 (de) 2002-09-15
EP0819002B1 (fr) 2002-08-28
CN1198612C (zh) 2005-04-27
ITRM950223A0 (it) 1995-04-07
JP4049390B2 (ja) 2008-02-20
MX9707712A (es) 1998-03-31
KR19980703707A (ko) 1998-12-05
ES2182967T3 (es) 2003-03-16
HUP9900733A3 (en) 2003-05-28
PT819002E (pt) 2003-01-31
CZ292020B6 (cs) 2003-07-16
EP0819002A1 (fr) 1998-01-21
TW450816B (en) 2001-08-21
NZ304107A (en) 2000-12-22
CZ316797A3 (cs) 1998-05-13
WO1996031210A1 (fr) 1996-10-10
AU5120096A (en) 1996-10-23
ITRM950223A1 (it) 1996-10-07
NO974603L (no) 1997-11-24
HUP9900733A2 (hu) 1999-07-28
IL117824A0 (en) 1996-08-04
IT1276522B1 (it) 1997-10-31
DE69623271D1 (de) 2002-10-02
US5891891A (en) 1999-04-06
PL322647A1 (en) 1998-02-16
DE69623271T2 (de) 2003-07-24
EA000396B1 (ru) 1999-06-24
DK0819002T3 (da) 2003-01-06
CN1183719A (zh) 1998-06-03
AU707759B2 (en) 1999-07-22
CA2217590A1 (fr) 1996-10-10
CA2217590C (fr) 2008-08-12
JPH11503149A (ja) 1999-03-23
NO974603D0 (no) 1997-10-06
IL117824A (en) 2000-08-31
NO315408B1 (no) 2003-09-01

Similar Documents

Publication Publication Date Title
HUP9900733A3 (en) Use of imidazo[1,2-a]pyridine-3-acetamide derivatives for the therapeutic treatment of neuropsychiatric syndromes associated with difunction of the neural circuits of the basal ganglia
ZA897699B (en) Pyrrolo(1,2-a)imidazole and imidazo(1,2-a)pyridine derivatives and their use as 5-lipoxygenase pathway inhibitors
ZA928832B (en) Local delivery of dipyridamole for the treatment of proliferative diseases
NO305886B1 (no) Anvendelse av et organisk nitritt for fremstilling av medikamenter for kontinuerlig, vasodilatorisk terapi
IL133800A0 (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
HU9401317D0 (en) Antiviral 2-ethyl - 1h imidazo (4,5-c) quinolin-4-amines
GB2305605B (en) Pipecolic acid derivatives for the treatment of neurological disorders
EP0524946A4 (en) Treatment of central nervous system disorders with imidazole angiotensin-ii receptor antagonists
FI92401B (fi) Menetelmä valmistaa farmakologisesti arvokasta pyrrolo/3,2,1-jk//1,4/bentsodiatsepiinijohdannaista
EP1027054A4 (fr) Apport local d'inhibiteurs de phosphodiesterases, dans le traitement du dysfonctionnement erectile
FI922848L (fi) Menetelmä valmistaa terapeuttisesti aktiivisia tetrahydropyrrolo[1,2-a]pyratsiini-4-spiro-3'-pyrrolidiinijohdannaisia
HUP0201280A3 (en) Use of pyridazino[4,5-b]indole-1-acetamide derivatives for preparing medicines for treating diseases related to the dysfunction of peripheral benzodiazepin receptors
IL104706A0 (en) 3-(1h-tetrazol-5-yl)-4h-pyrido(1,2-a)pyrimidine-4-ones and process for the preparation thereof
IL92078A0 (en) Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
HU9500171D0 (en) Tetracyclic compounds process and intermediated for their preparation and their use as antitumour agents
EP0577023A3 (en) Angiotensin-ii receptor-antagonists for the treatment of arrhythmices
AU4859596A (en) Imidazo{1,2-a}pyridines for the treatment of cns and cardiac diseases
ZA985818B (en) Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders.
EP0554098A3 (en) Process for the preparation of imidazo 4,5-b pyridine derivatives
HUP9901258A3 (en) Imidazo[2,1-b]thiazole and thiazolo[3,2-a]pyrimidine derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
EP0436831A3 (en) Imidazo(1,2-a)pyridinylalkyl compounds for treatment of neurotoxic injury
FI98816B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 4,5,6,7-tetrahydroimidatso [4,5,1-jk][1,4]bentsodiatsepin-2-oni ja -2-tionijohdannaisten valmistamiseksi
ZA937604B (en) 3,3-disubstituted tri and tetracyclic indolin-2-ones useful for the treatment of cognitive disorders
FI103277B1 (fi) Menetelmä terapeuttisesti käyttökelpoisten pyrrolo- ja tieno[3,2-c]naftyridiinijohdannaisten valmistamiseksi
FI93839B (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 2,3-dihydroksi-pyratsino/2,3-f/kinoksaliini- ja pyratsino/2,3-g//1,5/bentsodiatsepiinijohdannaisten valmistamiseksi